FDA
-
-
-
-
-
-
-
Helius Medical Technologies, Inc. Appoints Antonella Favit-Van Pelt, M.D., Ph.D. as Chief Medical Officer
-
-
-
-
-
-
-
Helius Medical Technologies, Inc. to Present at the Investor Summit Group’s Q1 Virtual Summit on March 23rd
-
-
-
-
-
-
-
Helius Medical Technologies, Inc. Regains Compliance with Nasdaq Listing Standards
-
-
-
-
-
-
-
Helius Medical Technologies, Inc. Announces the Expansion to a Total of 27 Authorized PoNS Treatment™ Clinic Locations Across Canada
-
-
-
-
-
-
-
Helius Medical Technologies, Inc. Announces Publication of Peer-Reviewed Study: Translingual Neural Stimulation with the Portable Neuromodulation Stimulator (PoNS™) Induces Structural Changes Leadin
-
-
-
-
-
-
-
Helius Medical Technologies, Inc. Announces FDA Has Granted the PoNS Device Breakthrough Device Designation for the Treatment of Gait Deficits Due to Symptoms of Multiple Sclerosis
-
-
-
-
-
-
-
Helius Medical Technologies Reports Preliminary Unaudited Fourth Quarter and Full Year Unaudited 2019 Financial Results, Provides Commercial and Regulatory Update and Announces Submission to Health Ca
-
322,901 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

